Treatment
S-1 clinical trials
We’re tracking 792 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT06640192RecruitingPhase 2
High-dose HIV drugs to clear hidden virus
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Madrid, MadridAges 18–60 - NCT06903923RecruitingPhase 2
Bone health in teens and young adults taking GLP-1 weight loss drugs
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
Charlottesville, VirginiaAges 12–21 - NCT06901622Enrolling by invitationPhase 2
Testing a combination of drugs for advanced gallbladder and bile duct cancer
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
ZhengzhouAges 18–75 - NCT06843512Recruiting
How GLP-1 meds change eating habits
This study looks at how starting a GLP-1 medication (like Wegovy or Ozempic) changes your food choices and eating habits. It may help you understand if these medicines work for weight loss.
State College, PennsylvaniaAges 18 years+ - NCT05486650Recruiting
Study of focused radiation after PD-1 treatment helped non-lung cancer
This observational study looks at how stereotactic (high-precision) radiation works for advanced non-small cell lung cancer that is stable after PD-1 antibody treatment (sometimes with chemotherapy). It may help doctors better understand which patients benefit from this next treatment step and what side effects to expect.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06794086RecruitingPhase 3
SBRT and immunotherapy for colorectal cancer liver metastases
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
Guangzhou, GuangdongAges 18–75 - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06774079RecruitingPhase 4
GLP-1 drug and diet study for Crohn's disease patients
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
Miami, FloridaAges 18 years+ - NCT06732856RecruitingPhase 1/Phase 2
Zolbetuximab plus chemo before stomach cancer surgery
This trial tests a new drug called zolbetuximab combined with chemotherapy (docetaxel, oxaliplatin, S-1) before surgery for people with locally advanced stomach cancer that has a specific protein (CLDN18.2). The goal is to see if this combination shrinks tumors enough to improve surgery outcomes.
SeoulAges 19 years+ - NCT05360082Recruiting
Brain scan study comparing two PET tracers in Huntington disease
This study compares two different brain imaging tracers to see which one shows Huntington disease brain changes better. It may help improve how doctors measure and track Huntington disease using PET-MRI scans.
LeuvenAges 20–75 - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT06740370Recruiting
TACE with lenvatinib and immunotherapy for ruptured liver cancer
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
Beijing, None SelectedAges 18–75 - NCT06730373RecruitingPhase 2
RC48 plus immunotherapy and chemotherapy for advanced stomach cancer
This study tests a combination of three treatments for advanced stomach cancer that is HER2-positive. The treatments are RC48, an antibody-drug conjugate that targets HER2 on cancer cells, sintilimab, which helps the immune system fight cancer, and S-1, a chemotherapy drug. The goal is to see if the combination is safe and effective as a first-line treatment.
Zhengzhou, HenanAges 18–75 - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06647680RecruitingPhase 2
Chemo and immunotherapy before surgery for rectal cancer
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
Qingdao, ShandongAges 18–75 - NCT06569862Recruiting
Comparing early vs. late dressing removal after abdominal surgery
This trial compares taking off the surgical dressing one day after surgery versus waiting about 6 days after elective (planned) abdominal surgery to see which approach reduces the risk of surgical site infections.
ParisAges 18 years+ - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Los Angeles, CaliforniaAges Up to 3 days - NCT06519591RecruitingPhase 2
New drug combo for stomach cancer with abdominal spread
This trial tests a combination of three drugs (given through a vein and a pill) plus a chemotherapy infusion directly into your belly for stomach cancer that has spread to the lining of the abdomen. It specifically looks at a marker called Claudin 18.2 to see if this treatment works better for people with that marker.
Shanghai, Huangpu DistrictAges 18 years+ - NCT06496373RecruitingEarly Phase 1
mRNA vaccine plus immunotherapy after pancreatic cancer surgery
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06502145RecruitingPhase 1
Iadademstat with hypomethylating agent for MDS
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
Milwaukee, WisconsinAges 18 years+ - NCT06471205RecruitingPhase 2
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06468280RecruitingPhase 2
Immunotherapy and chemo with surgery for limited-spread stomach cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) plus chemotherapy or targeted therapy, followed by surgery, for people with stomach cancer that has spread to a limited number of other sites. The goal is to see if this approach can help shrink the cancer enough to make surgery more effective.
Shanghai, Shanghai CityAges 18–79
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 792 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.